RECURRENT NASOPHARYNGEAL CARCINOMA
Clinical trials for RECURRENT NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink Hard-to-Treat throat cancer
Disease control TerminatedThis study tests whether adding the targeted therapy cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) can better control advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy an…
Matched conditions: RECURRENT NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy plus chemo shows promise for Tough-to-Treat nasopharyngeal cancer
Disease control OngoingThis phase II trial is testing whether combining an immunotherapy drug (PD-1 antibody) with standard chemotherapy and radiation can help people whose nasopharyngeal cancer has come back after initial treatment. The study includes 68 participants with high-risk recurrent cancer th…
Matched conditions: RECURRENT NASOPHARYNGEAL CARCINOMA
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo targets rare cancers in early trial
Disease control OngoingThis early-phase trial tests the combination of two drugs, vorinostat and azacitidine, in people with nasopharyngeal cancer or nasal NK-T cell lymphoma that has come back or spread. The main goal is to find the safest dose and see how the body responds. Only 18 participants are e…
Matched conditions: RECURRENT NASOPHARYNGEAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC